AstraZeneca to share latest data from an industry-leading portfolio that aims to advance clinical understanding of diabetes and CV risk management at ADA 2018

Key data evaluating the efficacy and safety of Farxiga (dapagliflozin) in combination with other type-2 diabetes therapies head-to-head vs. insulin or sulfonylurea

Latest data from the DEPICT clinical programme evaluating Farxiga to address an unmet need for oral therapy in adult patients with type-1 diabetes

Debut of pre-clinical and clinical data for MEDI0382 in type-2 diabetes, a potential first-in-class oxyntomodulin-like peptide

AstraZeneca and its global biologics research and development arm, MedImmune, will present 45 abstracts including seven late-breaking data disclosures from the Company’s Cardiovascular, Renal & Metabolism (CVRM) therapy area at the American Diabetes Association’s (ADA) 78th Scientific Sessions in Orlando, Florida, 22-26 June 2018.

This latest research will help to inform clinical practice with Farxiga (dapagliflozin) and Bydureon (exenatide extended-release) in type-2 diabetes (T2D), including data on their use alone and in combination with other diabetes therapies. Highlights also include data on the potential new use of Farxiga in type-1 diabetes (T1D) and the debut of pre-clinical and clinical data for MEDI0382, an oxyntomodulin-like peptide and potential new medicine. MEDI0382 has the potential to be a first-in-class therapy, and is the latest candidate to advance in the Company’s CVRM pipeline.

Commenting on AstraZeneca’s scientific approach in CVRM, Ludovic Helfgott, Vice President, Cardiovascular, Renal and Metabolism, said: “At ADA this year, we are sharing data on novel approaches and potential new medicines as we continue to advance treatments for patients with diabetes. At AstraZeneca, we recognise the critical interconnectivity between cardiovascular, renal and metabolic diseases, and aim to deliver leading science that addresses patient needs across the global burden of these conditions.”

Clinical and real-world evidence data further evaluating Farxiga in T2D

Highlights include several abstracts evaluating the effects of Farxiga on glycaemic control and additional endpoints, including blood pressure and body weight, alone and in combination with other diabetes treatments across a broad range of patients.

Presentations assessing the combination of Farxiga and Onglyza (saxagliptin) include 24-week results of Farxiga as add-on therapy to Onglyza, in addition to metformin compared with insulin in patients with or without sulfonylurea therapy.

AstraZeneca will also present long-term data from the DURATION-8 trial over 104 weeks (Late-breaking Poster 104-LB), which evaluated the efficacy and safety of Farxiga once daily in combination with weekly Bydureon vs. each treatment alone.

New analyses from the EXSCEL (Exenatide Study of Cardiovascular Event Lowering) cardiovascular (CV) outcomes trial will be presented in a late-breaking poster, which will evaluate the CV and renal effects in patients that received an SGLT-2 inhibitor (SGLT-2i) in the placebo (non-exenatide) group, and a moderated poster will provide insights on the renal outcomes observed with Bydureon.

A new analysis of the landmark CVD-REAL study, presented as a late-breaking poster comparing the risk of all-cause mortality, hospitalisation for heart failure (hHF), myocardial infarction and stroke in patients with T2D starting treatment with Farxiga vs. any DPP-4 inhibitor, is based on data from Canada, Israel, Japan and South Korea. CVD-REAL provides real-world evidence of Farxiga on these CV outcomes, while DECLARE (Dapagliflozin Effect on CardiovascuLAR Events) will evaluate the CV efficacy and safety of Farxiga in the largest SGLT-2i CV outcomes trial in a broad range of patients with T2D, including those with multiple CV risk factors or established CV disease. The trial is anticipated to read out in the second half of 2018.

Data evaluating the potential of Farxiga to address an unmet need in patients with T1D

Currently, there are no oral treatment options approved for adult patients with T1D. The latest data from the DEPICT (Dapagliflozin Evaluation in Patients with Inadequately Controlled Type-1 Diabetes) clinical programme will include results on the efficacy and safety of Farxiga as add on to insulin over 52 weeks (from DEPICT-1) and 24 weeks (from DEPICT-2), as well as a pooled analysis of continuous glucose monitoring data from both trials. Farxiga is not approved for T1D.

First pre-clinical and clinical data for MEDI0382 in T2D

From the Company’s promising CVRM pipeline, MedImmune will present primary results from its MEDI0382 Phase IIa trial. MEDI0382 is an oxyntomodulin-like peptide and potential new medicine designed to simultaneously activate the glucagon-like peptide 1 (GLP-1) and glucagon (GLU) receptors, with the goals of achieving glucose control, reduced body weight and increased energy expenditure in patients with T2D. Oxyntomodulin is a peptide hormone released from the gut that targets the GLP-1 and glucagon receptors, both of which are critical to controlling metabolic functions. In addition, two oral presentations will feature data on the effects of MEDI0382 on hepatic (liver) fat in patients with T2D, and its effects on pancreatic and incretin hormones, respectively.

Details of the key abstracts from AstraZeneca/MedImmune:

Abstract title

Presentation details

Short-term and long-term data for Farxiga in combination with other antidiabetic agents in T2D

 

Effect of Dapagliflozin Plus Saxagliptin vs. Insulin Glargine on A1C in patients With Type-2 Diabetes Inadequately Controlled by Metformin with or without Sulfonylurea

 

Oral 260-OR, Monday, June 25, 09:30 - 09:45 EDT

Dapagliflozin Plus Saxagliptin Add-On vs. Glimepiride Add-On to Metformin in Patients with Poorly Controlled Type-2 Diabetes

 

Oral 261-OR, Monday, June 25, 09:45 - 10:00 EDT

 

Durability of Glycemic Control with Dapagliflozin vs Saxagliptin in Patients with Inadequately Controlled Type-2 Diabetes

 

Poster 1181-P, Sunday, June 24, 12:00 - 13:00 EDT

Triple vs. Dual Therapy with Low-Dose Dapagliflozin Plus Saxagliptin vs. Each Monocomponent Added to Metformin in Uncontrolled Type-2 Diabetes

 

Poster 1149-P, Sunday, June 24, 12:00 - 13:00 EDT

DURATION-8 Randomised Controlled Trial 104-Week Results: Once-Weekly Exenatide (ExQW) Plus Once-Daily Dapagliflozin (DAPA) Versus ExQW or DAPA Alone

 

Late-breaking Poster 104-LB, Monday, June 25, 12:00 - 13:00 EDT

 

Analyses of renal and SGLT-2i outcomes in the EXSCEL trial

 

Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group

 

Late-breaking Poster 130-LB, Monday, June 25, 12:00 - 13:00 EDT

Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group

 

Late-breaking Poster 130-LB, Monday, June 25, 12:00 - 13:00 EDT

 

Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)

 

Poster 522-P, General Session, Saturday, June 23, 11:30 - 12:30 EDT and Moderated Poster Session, Monday, June 25, 12:00 - 13:00 EDT

 

 

Real-world evidence evaluating CV outcomes with SGLT2i vs. DPP-4

 

Analysis of Risk of CV Events and Death Associated with Initiation of SGLT-2 vs. DPP-4 Inhibitors from the CVD-REAL 2 Study

 

Late-breaking Poster 124-LB, Monday, June 25, 12:00 - 13:00 EDT

 

Short-term and long-term data for dapagliflozin in T1D

 

Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type-1 Diabetes: DEPICT-2 Study

 

Oral 213-OR, Sunday, June 24, 16:00 EDT

Long-Term Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type-1 Diabetes: The DEPICT-1 Study

 

Late-breaking Poster 119-LB, Monday, June 25, 12:00 - 13:00 EDT

Glucose Variables in T1D Studies with Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data from DEPICT-1 and 2

 

Late-breaking Poster 125-LB, Monday, June 25, 12:00 - 13:00 EDT

 

Clinical and pre-clinical data for MEDI0382, a novel oxyntomodulin-like (OXM) peptide

 

Effect of MEDI0382 on Hepatic Fat Content in Subjects with Type-2 Diabetes Mellitus

 

Oral 78-OR, Saturday, June 23, 08:00 - 10:00 EDT

Effects of MEDI0382 on Insulin, Glucagon and Incretin Hormone Profiles

Oral 79-OR, Saturday, June 23, 08:00 - 10:00 EDT

 

Evaluation of Glucose Control and Weight Loss with MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, in a 6-week Phase 2A Study of T2DM Subjects

 

Poster 1067-P, Sunday, June 24, 12:00 PM - 13:00 EDT

 

Latest analyses of the leading global diabetes registries

 

Vascular Events in Patients with Type-2 Diabetes in the Year Following Initiation of Second-line Therapy: the DISCOVER Study

 

Poster 1562-P, Sunday, June 24, 12:00-13:00 EDT

Composite Cardiovascular Risk Factor Target Achievement and its Indicators in US Adults with Diabetes: The Diabetes Collaborative Registry

 

Poster 1487-P, Sunday, June 24, 12:00 - 13:00 EDT

 

CV outcomes and mortality in T2D with associated CV, renal and metabolic co-morbidities

 

Cardiovascular Outcomes and Mortality in Type-2 Diabetes with Associated Cardio-Renal-Metabolic Co-Morbidities

 

Poster 1582-P, Sunday, June 24, 12:00 - 13:00 EDT

 

 

The full list of AstraZeneca/MedImmune scientific data can be accessed on the ADA website here. You can also follow us live during ADA 2018 on Twitter and LinkedIn.

 

– ENDS –

 

NOTES TO EDITORS

 

About AstraZeneca in Cardiovascular, Renal & Metabolism (CVRM)

Cardiovascular, renal and metabolic diseases together form one of AstraZeneca’s main therapy areas and platforms for future growth. By following the science to understand more clearly the underlying links between the heart, kidney and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. Our ambition is to modify or halt the natural course of CVRM diseases and even regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

About MedImmune

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular, Renal and Metabolic Diseases, and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers, with additional sites in Cambridge, UK and South San Francisco, CA. For more information, please visit www.medimmune.com.

 

Media Relations

 

 

Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Gonzalo Viña

UK/Global

+44 203 749 5916

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

 

 

 

Investor Relations

 

 

Thomas Kudsk Larsen

 

 

+44 203 749 5712

Josie Afolabi

 

+44 203 749 5631

Craig Marks

Finance; Fixed Income; M&A

+44 7881 615 764

Henry Wheeler

Oncology

+44 203 749 5797

Mitchell Chan

Oncology; Other

+1 240 477 3771

Christer Gruvris

Brilinta; Diabetes

+44 203 749 5711

Nick Stone

Respiratory; Renal

+44 203 749 5716

Jennifer Kretzmann

Retail Investors

+44 203 749 5824

US toll-free

 

+1 866 381 7277

 

tags

  • Hjärta Kärl